These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25601343)

  • 1. Adjuvant treatment for HER2-positive breast cancer.
    Burki TK
    Lancet Oncol; 2015 Feb; 16(2):e59. PubMed ID: 25601343
    [No Abstract]   [Full Text] [Related]  

  • 2. Dual HER2 inhibition and paclitaxel in metastatic breast cancer.
    Brower V
    Lancet Oncol; 2015 Feb; 16(2):e57. PubMed ID: 25577955
    [No Abstract]   [Full Text] [Related]  

  • 3. New developments in adjuvant therapy for breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2005 Sep; 3(9):688-90. PubMed ID: 16224442
    [No Abstract]   [Full Text] [Related]  

  • 4. HER2 and response to paclitaxel in node-positive breast cancer.
    Roukos DH
    N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18193530
    [No Abstract]   [Full Text] [Related]  

  • 5. HER2 and response to paclitaxel in node-positive breast cancer.
    Ferretti G; Felici A; Cognetti F
    N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18184969
    [No Abstract]   [Full Text] [Related]  

  • 6. HER2 and response to paclitaxel in node-positive breast cancer.
    Nash I
    N Engl J Med; 2008 Jan; 358(2):198; author reply 198-9. PubMed ID: 18193532
    [No Abstract]   [Full Text] [Related]  

  • 7. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
    Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
    Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
    [No Abstract]   [Full Text] [Related]  

  • 8. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
    Altundag K; Baptista MZ
    Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
    [No Abstract]   [Full Text] [Related]  

  • 9. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
    Jiang ZF; Shao ZM; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):158-60. PubMed ID: 20403251
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
    Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR
    Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab plus chemotherapy improves survival in early-stage HER2-positive breast cancer patients.
    Oncology (Williston Park); 2005 Jun; 19(7):851, 862. PubMed ID: 16053034
    [No Abstract]   [Full Text] [Related]  

  • 13. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
    Paplomata E; Nahta R; O'Regan RM
    Cancer; 2015 Feb; 121(4):517-26. PubMed ID: 25346473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 and response to paclitaxel in node-positive breast cancer.
    Hayes DF; Thor AD; Dressler LG; Weaver D; Edgerton S; Cowan D; Broadwater G; Goldstein LJ; Martino S; Ingle JN; Henderson IC; Norton L; Winer EP; Hudis CA; Ellis MJ; Berry DA;
    N Engl J Med; 2007 Oct; 357(15):1496-506. PubMed ID: 17928597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
    Wang LP; Shen KW; Shen ZZ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):241-3. PubMed ID: 16875618
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant systemic therapies in breast cancer.
    Hernandez-Aya LF; Gonzalez-Angulo AM
    Surg Clin North Am; 2013 Apr; 93(2):473-91. PubMed ID: 23464697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
    Khasraw M; Bell R
    Expert Rev Anticancer Ther; 2012 Aug; 12(8):1005-13. PubMed ID: 23030220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.